MONTREAL, CANADA -- (Marketwire) -- 02/05/13 -- Theratechnologies Inc. (TSX:TH) announced today that the delisting of its common shares on the NASDAQ Global Market (NASDAQ) is completed. Theratechnologies' common shares continue trading on the Toronto Stock Exchange (TSX) under the trading symbol "TH".

On January 14, 2013, we announced our intent to voluntarily delist our common shares from the NASDAQ and a Form 25 was subsequently filed on January 28, 2013, with the Securities and Exchange Commission (SEC). Notwithstanding the delisting of our common shares from the NASDAQ, we will continue filing our periodic documents as a foreign private issuer with the SEC pursuant to Sections 15(d) of the Securities Exchange Act of 1934, as amended, (Exchange Act) for at least 12 months until we can demonstrate that our shareholdings is comprised of less than 300 persons resident in the United States or that the average daily trading volume of our common shares in the United States over that 12-month period is no greater than five percent of the average daily trading volume of our common shares on a worldwide basis.

About Theratechnologies

Theratechnologies (TSX:TH) is a biopharmaceutical company that specializes in innovative therapeutic peptide products, with an emphasis on growth-hormone releasing factor peptides. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR at www.sedar.com and on the SEC's website at www.sec.gov.

Forward-Looking Information

This press release contains certain statements that are considered "forward-looking information" within the meaning of applicable securities legislation, which statements may contain such words as "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions. This forward-looking information includes, but is not limited to, information regarding the continuous trading of our common shares on the TSX, our continuous reporting with the SEC and our capacity to cease our reporting with the SEC.

Forward-looking information is based upon a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond Theratechnologies' control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. These assumptions include, but are not limited to, the fact that we will remain in good standing with securities laws applicable to us and the rules and regulation of the TSX, that no cease trading order will be issued against us, that we incur no financial difficulty leading us to seek exemptions from our reporting obligations and that we can meet the requirements described under Rule 12h-6(a)(4) of the Exchange Act to cease reporting with the SEC. These risks and uncertainties include, but are not limited to, the risk that we are unable to comply with securities laws and the rules and regulations of the TSX, that a cease trading order is issued against us and that we cannot meet the requirements described under Rule 12h-6(a)(4) of the Exchange Act to cease reporting with the SEC.

Theratechnologies refers potential investors to the "Risk Factors" section of its Annual Information Form (AIF) dated February 27, 2012. The AIF is available at www.sedar.com and at www.sec.gov under Theratechnologies' public filings. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-looking information reflects current expectations regarding future events and speaks only as of the date of this press release and represents Theratechnologies' expectations as of that date.

Theratechnologies undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law.